Nebkliq (Amlodipine Besilate, Nebivolol Hydrochloride)

Amlodipine besilate and nebivolol hydrochloride, the active ingredients in Nebkliq, are a calcium‑channel blocker and a beta‑blocker presented as an oral tablet for systemic use. They treat hypertension in adult patients by lowering blood pressure and reducing cardiac workload.

GNH USA supplies Nebkliq as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebkliq combines a calcium‑channel blocker and a beta‑blocker to manage elevated blood pressure.

Hypertension: provides sustained reduction of systolic and diastolic pressure in adults. Essential hypertension: improves long‑term blood pressure control and reduces cardiovascular risk. Isolated systolic hypertension: lowers high systolic values while maintaining diastolic stability.

Nebkliq may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Peripheral edema: swelling of ankles or feet. - Dizziness or light‑headedness, especially on standing. - Flushing: transient warmth and redness. - Fatigue or tiredness. - Nausea or abdominal discomfort.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure. - Bradycardia: unusually slow heart rate. - Heart block or atrioventricular conduction disturbances. - Angioedema: swelling of face, lips, or throat. - Hepatic dysfunction: abnormal liver enzymes. - Allergic reactions: rash, itching, or anaphylaxis.

Before initiating Nebkliq, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Blood pressure monitoring: check regularly to avoid excessive hypotension. - Cardiac assessment: review heart rate and conduction status. - Hepatic impairment: adjust use in patients with liver disease. - Concomitant antihypertensives: avoid additive effects that may cause severe hypotension. - Abrupt discontinuation: taper gradually to prevent rebound hypertension. - Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Nebkliq can interact with several medicines; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels. - Non‑dihydropyridine calcium channel blockers (e.g., verapamil, diltiazem): risk of excessive bradycardia. - Other antihypertensives (e.g., ACE inhibitors, ARBs) at high doses: may cause profound hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - NSAIDs or COX‑2 inhibitors: can blunt antihypertensive effect. - Diuretics: may enhance electrolyte disturbances. - Antidiabetic agents: monitor glucose as blood pressure changes can affect glycemic control.